Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524600 | 0.84 | LMNA (0.62) | POLBRAB9AMEN1KMT2ALMNA | |
| SCHEMBL5533361 | 0.83 | POLB (0.65) | POLBRAB9AMEN1KMT2ALMNA | |
| SCHEMBL5463743 | 0.81 | MAPT (0.77) | POLBRAB9AKMT2ALMNAGAA | |
| SCHEMBL31680577 | 0.78 | POLB (0.70) | POLBRAB9AEPHX2MAPT | |
| SCHEMBL16323107 | 0.76 | LMNA (0.97) | MEN1KMT2ALMNAGAAEPHX2 | |
| SCHEMBL5523816 | 0.74 | LMNA (0.57) | POLBRAB9ALMNAGAAMAPT | |
| Ticarbodine SCHEMBL636894 | 0.74 | MEN1 (0.61) | POLBRAB9AMEN1KMT2ALMNA | |
| SCHEMBL5531540 | 0.74 | MAPT (0.67) | POLBLMNAGAAEPHX2L3MBTL1 | |
| SCHEMBL11419110 | 0.74 | POLB (0.62) | POLBRAB9AKMT2ALMNAGAA | |
| SCHEMBL5526949 | 0.74 | ABCC1 (0.63) | POLBMEN1KMT2ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | POLB 4518/4885RAB9A 902/4885MEN1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.